Plavix

Plavix
Name	Plavix
Tradename	Plavix
Generic name	clopidogrel
Drug class	Antiplatelet agent
Routes of administration	Oral
Legal status	Prescription-only

Plavix is a widely prescribed antiplatelet medication used to reduce the risk of thrombotic cardiovascular events. It is a thienopyridine prodrug that irreversibly inhibits platelet aggregation and is commonly prescribed after acute coronary syndromes and percutaneous coronary intervention. The drug has been the subject of extensive clinical trials, regulatory review, and pharmacogenomic investigation.

Medical uses

Plavix is indicated to prevent atherothrombotic events in patients with recent myocardial infarction, recent ischemic stroke, or established peripheral arterial disease; it is also used in conjunction with aspirin following percutaneous coronary intervention with stent placement. Key clinical trials and guideline updates from organizations such as American College of Cardiology, American Heart Association, European Society of Cardiology, World Health Organization, and National Institute for Health and Care Excellence have shaped its indications. Comparative effectiveness studies involving drugs evaluated by Food and Drug Administration, European Medicines Agency, Heart and Stroke Foundation, and academic centers like Mayo Clinic, Cleveland Clinic, and Johns Hopkins Hospital informed recommendations on dual antiplatelet therapy duration and patient selection. Use in acute coronary syndrome settings was influenced by outcomes from studies published in journals associated with New England Journal of Medicine, The Lancet, and Journal of the American Medical Association.

Pharmacology

Plavix is a prodrug metabolized hepatically to an active thiol metabolite that irreversibly antagonizes the P2Y12 subtype of adenosine diphosphate receptors on platelets, reducing platelet activation and aggregation. Key metabolic enzymes include cytochrome P450 isoforms such as CYP2C19, CYP3A4, CYP1A2, CYP2B6, and CYP2C9, and pharmacogenomic variation in CYP2C19 alleles documented by groups like Human Genome Project and Pharmacogenomics Knowledgebase affects response. Mechanistic insights were advanced by researchers affiliated with institutions such as University of Oxford, Harvard Medical School, Stanford University School of Medicine, Massachusetts General Hospital, and University of California, San Francisco. The drug’s platelet inhibition profile has been compared to other agents studied at centers like Brigham and Women's Hospital, Karolinska Institutet, and Imperial College London.

Dosage and administration

Typical dosing regimens adopted in practice guidelines from American College of Cardiology and European Society of Cardiology include a 300–600 mg loading dose followed by a 75 mg once-daily maintenance dose for adults. Dosing adjustments and perioperative management are guided by recommendations from Society for Cardiovascular Angiography and Interventions, American Society of Hematology, European Medicines Agency, and local formularies at hospitals such as Johns Hopkins Hospital and Cleveland Clinic. Special-population considerations have been addressed in guidance from World Health Organization, National Institutes of Health, Centers for Disease Control and Prevention, and specialty societies like American Geriatrics Society and American College of Chest Physicians.

Adverse effects and contraindications

Bleeding, including gastrointestinal hemorrhage and intracranial hemorrhage, is the primary serious adverse effect reported in trials published in venues such as New England Journal of Medicine and The Lancet and monitored by regulators like Food and Drug Administration and European Medicines Agency. Other reported adverse events include neutropenia identified in postmarketing surveillance by agencies such as Medicines and Healthcare products Regulatory Agency and hematologic complications discussed at meetings of American Society of Hematology and European Hematology Association. Contraindications and cautions appear in labeling reviewed by Food and Drug Administration, European Medicines Agency, and national formularies including NHS England and Canadian Agency for Drugs and Technologies in Health.

Interactions

Plavix’s efficacy and safety are affected by coadministration with drugs and substances that alter CYP2C19 or platelet function. Interacting agents include proton pump inhibitors evaluated by researchers at Mayo Clinic and regulatory communications from Food and Drug Administration; anticoagulants such as those assessed by American Society of Hematology; nonsteroidal anti-inflammatory drugs studies involving Cochrane Collaboration; and other P2Y12 inhibitors discussed in comparative trials by European Society of Cardiology. Drug–drug interaction signals have been examined in pharmacovigilance databases maintained by World Health Organization and national agencies like Food and Drug Administration and Medicines and Healthcare products Regulatory Agency.

History and development

Plavix was developed through collaborations between pharmaceutical companies and academic laboratories, with pivotal trials and development programs involving investigators at Université de Rennes, Université Paris-Saclay, University of Tokyo, Duke University School of Medicine, Columbia University, and industry sponsors reviewed by Food and Drug Administration and European Medicines Agency. Key clinical trial publications and conference presentations at American Heart Association and European Society of Cardiology meetings documented its efficacy. Subsequent pharmacogenomic research linking CYP2C19 variants to response emerged from consortia including International HapMap Project contributors and institutions such as Johns Hopkins University, Stanford University, and Harvard Medical School.

Regulatory status and brand information

Plavix was approved and marketed globally with regulatory approvals by agencies including the Food and Drug Administration, European Medicines Agency, Health Canada, Therapeutic Goods Administration (Australia), and national authorities across countries like Japan, Brazil, India, China, and South Africa. Brand and generic availability evolved as patents expired and generic manufacturers entered markets regulated by authorities such as United States Patent and Trademark Office and procurement bodies like National Health Service (England). Postmarketing surveillance and label updates were coordinated with institutions such as World Health Organization, Food and Drug Administration, and European Medicines Agency.

Category:Antiplatelet agents